Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeikagakuTSE:4548 -0.14%72 Debt-to-Equity is 0.01 as of Mar. 2026, which is at its 10-year median of 0.01. GuruFocus rates TSE:4548 with a GF Score™ of 72/100 and a GF Value™ of 円776.89 (Fairly Valued). The stock has 5 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Seikagaku ranks better than 99.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Seikagaku's Debt-to-Equity or its related term are showing as below:
TSE:4548'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.01
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Seikagaku was 0.01. The lowest was 0.00. And the median was 0.01.
TSE:4548's Debt-to-Equity is ranked better than 99.86% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs TSE:4548: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Seikagaku Debt-to-Equity Related Terms
Seikagaku Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Seikagaku's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4548 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Seikagaku's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seikagaku Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Seikagaku's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seikagaku (TSE:4548) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Seikagaku and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, Seikagaku ranks #1 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Seikagaku's Debt-to-Equity too high?
Seikagaku's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Seikagaku's value of 0.01 is 95.8% below this industry median. Based on the distribution chart, Seikagaku ranks #1 out of 699 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Seikagaku has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seikagaku's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Seikagaku ranks #1 out of 699 companies for Debt-to-Equity. This places Seikagaku in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.24. Seikagaku's value of 0.01 is 95.8% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.24, Seikagaku has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current Debt-to-Equity of 0.01 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Seikagaku and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seikagaku stock overvalued right now?
Based on GuruFocus' analysis, Seikagaku (TSE:4548) is currently considered Fairly Valued. The stock's GF Value™ is 円776.89, compared to a current price of 円705.00 — trading 9.3% below its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 95.8% below the Medical Devices & Instruments industry median of 0.24. Seikagaku's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Seikagaku (TSE:4548), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seikagaku (TSE:4548) Overvalued in 2026?
Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued.
The current stock price of 円705.00 is trading 9.3% below its estimated GF Value™ of 円776.89.
GuruFocus considers Seikagaku to be Fairly Valued.
Key valuation signals for TSE:4548:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: 円776.89 vs. price of 円705.00 (9.3% below fair value)
Industry Position: 95.8% below the Medical Devices & Instruments median (#1 of 699)
No single metric tells the full story. See the TSE:4548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
72GF Score
Get the complete analysis for TSE:4548
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4548 has been successfully added to your 
